![\"\"](\"https:\/\/primexnewsnetwork.com\/wp-content\/uploads\/2023\/10\/image-149.jpg\")
<\/p>\n<\/p>\n
Product Range \u2013 Tinefcon<\/strong>\u00a0<\/p>\n \u2022 \u00a0 \u00a0Lord\u2019s Mark Biotech, the exclusive distribution marketing partner for Tinefcon in India.<\/em><\/p>\n \u2022\u00a0 \u00a0\u00a0To set up a task force of scientific communicators to build awareness about difficult-to-<\/em><\/p>\n treat skin conditions like Psoriasis.<\/em><\/p>\n \u2022 \u00a0 \u00a0Has set a revenue target of Rs. 100 crores for Tinefcon by 2025.<\/em><\/p>\n Mumbai (Maharashtra) [India], October 31:\u00a0\u00a0<\/strong>Lord\u2019s Mark Biotech, a subsidiary of Lord\u2019s Mark Industries and a leading Healthcare and wellness company has launched Tinefcon, a patented medicine for treating Psoriasis. Lord\u2019s Mark Biotech has signed an exclusivity agreement with INVEX Health Pvt Ltd for patented product developed by\u00a0Piramal life sciences<\/strong>\u00a0in India. Tinefcon is being launched as a total solution for Psoriasis in 4 forms such as tablet, cream, shower gel and scalp wash and is priced in the range of Rs. 799 \u2013 Rs. 3900.<\/p>\n Lord\u2019s Mark Biotech, the exclusive distribution partner for Tinefcon, is mentoring mentors around the country through a scientific sales force exclusively recruited for Tinefcon to deliver a solution for Psoriasis. The company has also established a strong social media campaign to aggressively market Tinefcon online. Tinefcon will also be offered on internet marketplaces, allowing the medical community to reliably recommend it to needy patients. \u00a0<\/p>\n Lord\u2019s Mark Biotech has invested Rs. 20 Crores to market and distribute it extensively in India, the company is expecting a revenue of Rs. 100 crores for Tinefcon by 2025.<\/p>\n Commenting on the launch,\u00a0Mr. Sachidanand Upadhyay, MD, Lord\u2019s Mark Biotech<\/strong>, said,\u00a0\u201cWe are pleased to introduce Tinefcon to the Indian market. The launch of Tinefcon is in line with our mission to enrich healthcare discourse in India. With Tinefcon, we offer a comprehensive, safe, and effective treatment of psoriasis. Our goal is to position Tinefcon as the principal choice for psoriasis management. We\u2019re looking forward to making Tinefcon a major success in India and reaching out to a wider patient base as we expand our presence.\u2019\u2019<\/em><\/p>\n Tinefcon, is being tested in 500+ patients across India, has been proven to treat psoriasis, and has shown a reduction of 66% in epidermal thickness, improved the Psoriasis Area Severity Index (PASI), and downregulated the psoriatic markers gene in a 12-week clinical study. Tinefcon can be safely prescribed to all patients over 18 years old.<\/p>\n Patient population and frequency of the disease:<\/strong>\u00a0Psoriasis commonly affects individuals in their 30\u2019s or 40\u2019s, with males being affected two times more commonly than females. Psoriasis prevalence is 1.6% among people aged 20 to 29 years and 4.3% among those aged 50 to 59 years. 125 million people worldwide\u20142 to 3 percent of the total population\u2014have psoriasis, according to the World Psoriasis Day consortium.<\/p>\n Psoriasis prevalence among US adults 20 years of age or older was 3.0%. Based on the 2020 US census data, this outcome translates to an estimated 7.55 million US adults with psoriasis, followed by a prevalence of 0.44\u20132.8% in India (approximately 4 crore people), which suggests India is second highest after the US.<\/p>\n If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Product Range \u2013 Tinefcon\u00a0 \u2022 \u00a0 \u00a0Lord\u2019s Mark Biotech, the exclusive distribution marketing partner for Tinefcon in India. \u2022\u00a0 \u00a0\u00a0To set up a task force of scientific communicators to build […]<\/p>\n","protected":false},"author":1,"featured_media":28546,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_rishi_post_view_count":274},"categories":[9],"tags":[674],"class_list":["post-28545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-pressrelease","rishi-post"],"rishi__cb_customizer_meta":"","comments_count":"0","_links":{"self":[{"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/posts\/28545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/comments?post=28545"}],"version-history":[{"count":0,"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/posts\/28545\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/media\/28546"}],"wp:attachment":[{"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/media?parent=28545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/categories?post=28545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newswiredelhi.com\/index.php\/wp-json\/wp\/v2\/tags?post=28545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}